RemeGen Co (HKSE:09995) Beginning Cash Position : HK$719 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Beginning Cash Position?

RemeGen Co's Beginning Cash Position for the quarter that ended in Dec. 2024 was HK$719 Mil.

RemeGen Co's quarterly Beginning Cash Position declined from Dec. 2023 (HK$1,225 Mil) to Jun. 2024 (HK$782 Mil) and declined from Jun. 2024 (HK$782 Mil) to Dec. 2024 (HK$719 Mil).

RemeGen Co's annual Beginning Cash Position increased from Dec. 2022 (HK$1,962 Mil) to Dec. 2023 (HK$2,263 Mil) but then declined from Dec. 2023 (HK$2,263 Mil) to Dec. 2024 (HK$776 Mil).

RemeGen Co Beginning Cash Position Historical Data

The historical data trend for RemeGen Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Beginning Cash Position Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

40.95

3,389.96

1,961.87

2,263.23

775.72

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Beginning Cash Position	Get a 7-Day Free Trial								2,892.25	2,263.23	1,224.66	782.17	718.89

RemeGen Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

RemeGen Co Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

Executives

I-nova Limited	2101 Beneficial owner
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Lin Jian	2103 Interests held jointly with another person
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Wang Liqiang	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Xudong	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you
Allianz Se	2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines